Therapy for fungal diseases: Opportunities and priorities

Trends in Microbiology

Volumn 18, Issue 5, 2010, Pages 195-204

  Denning, David W ^a   Hope, William W ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALLYLAMINE DERIVATIVE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; ANTIFUNGAL AGENT; CASPOFUNGIN; CLOTRIMAZOLE; CORTICOSTEROID; ECHINOCANDIN; FLUCONAZOLE; FLUCYTOSINE; IMIDAZOLE DERIVATIVE; ITRACONAZOLE; KETOCONAZOLE; MICAFUNGIN; MICONAZOLE; NYSTATIN; POLYENE; POSACONAZOLE; PYRIMIDINE DERIVATIVE; TERBINAFINE; TRIAZOLE DERIVATIVE; VORICONAZOLE;

ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS; ANTIFUNGAL ACTIVITY; ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; AREA UNDER THE CURVE; ASPERGILLOMA; ASTHMA; BACTERIAL INFECTION; BLASTOMYCOSIS; BONE MARROW SUPPRESSION; CANDIDURIA; CLINICAL TRIAL; COCCIDIOIDOMYCOSIS; CONFUSION; CRYPTOCOCCAL MENINGITIS; CRYPTOCOCCOSIS; DERMATOPHYTOSIS; DIARRHEA; DRUG BIOAVAILABILITY; DRUG CHOICE; DRUG EFFICACY; DRUG ERUPTION; DRUG METABOLISM; DRUG RESEARCH; DRUG STRUCTURE; ESOPHAGUS CANDIDIASIS; FLUID RETENTION; GASTROINTESTINAL SYMPTOM; HALLUCINATION; HEART LEFT VENTRICLE FAILURE; HISTOPLASMOSIS; HUMAN; HYPOKALEMIA; INVASIVE ASPERGILLOSIS; INVASIVE CANDIDIASIS; LIVER FUNCTION TEST; LIVER TOXICITY; LUNG ASPERGILLOSIS; MUCOCUTANEOUS CANDIDIASIS; MUCORMYCOSIS; MYCOSIS; NAUSEA; NEPHROTOXICITY; NONHUMAN; ONYCHOMYCOSIS; PHLEBITIS; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SIDE EFFECT; SINGLE DRUG DOSE; SPOROTRICHOSIS; TASTE DISORDER; THRUSH; VAGINA CANDIDIASIS; VISUAL DISORDER;

ANTIFUNGAL AGENTS; BIOMEDICAL RESEARCH; DRUG DISCOVERY; DRUG RESISTANCE, FUNGAL; MYCOSES;

BACTERIA (MICROORGANISMS); CANDIDA;

EID: 77952547165     PISSN: 0966842X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tim.2010.02.004     Document Type: Review

References (100)

1. Park B.J., et al. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. Aids 2009, 23:525-530.
2. Agarwal R., et al. Aspergillus hypersensitivity and allergic bronchopulmonary aspergillosis in patients with bronchial asthma: systematic review and meta-analysis. Int. J. Tuberc. Lung Dis. 2009, 13:936-944.
3. Vicente M.F., et al. Microbial natural products as a source of antifungals. Clin. Microbiol. Infect. 2003, 9:15-32.
4. Chain E., et al. Penicillin as a chemotherapeutic agent. Lancet 1940, 236:226-228.
5. Medoff, G. and Kobayashi, G.A. (1980) The Polyenes in Antifungal Chemotherapy. John Wiley & Sons.
6. Donovick R., et al. Amphotericins A and B, antifungal antibiotics produced by a streptomycete. I. In vitro studies. Antibiot. Annu. 1955, 3:579-586.
7. Torrado J.J., et al. Amphotericin B formulations and drug targeting. J. Pharm. Sci. 2008, 97:2405-2425.
8. Groll A.H., et al. Comparative drug disposition, urinary pharmacokinetics and renal effects of multilamellar liposomal nystatin and amphotericin B deoxycholate in rabbits. Antimicrob. Agents Chemother. 2003, 47:3917-3925.
9. Gershkovich P., et al. Pharmacokinetics and biodistribution of amphotericin B in rats following oral administration in a novel lipid-based formulation. J. Antimicrob. Chemother. 2009, 64:101-108.
10. Groll A.H., et al. Compartmentalized intrapulmonary pharmacokinetics of amphotericin B and its lipid formulations. Antimicrob. Agents Chemother. 2006, 50:3418-3423.
11. Wingard J.R., et al. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group. Clin. Infect. Dis. 2000, 31:1155-1163.
12. Cornely O.A., et al. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin. Infect. Dis. 2007, 44:1289-1297.
13. Kuse E.R., et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet 2007, 369:1519-1527.
14. Verweij P.E., et al. In vitro activities at pH 5.0 and pH 7.0 and in vivo efficacy of flucytosine against Aspergillus fumigatus. Antimicrob. Agents Chemother. 2008, 52:4483-4485.
15. Vandevelde A.G., et al. 5-fluorocytosine in the treatment of mycotic infections. Ann. Intern. Med. 1972, 77:43-51.
16. Hope, W.W. (2010) Flucytosine (5-fluorocytosine; 5FC). In Kucers' the Use of Antibiotics.
17. Normark S., Schonebeck J. In vitro studies of 5-fluorocytosine resistance in Candida albicans and Torulopsis glabrata. Antimicrob. Agents Chemother. 1972, 2:114-121.
18. Stamm A.M., et al. Toxicity of amphotericin B plus flucytosine in 194 patients with cryptococcal meningitis. Am. J. Med. 1987, 83:236-242.
19. Perfect, J.R. et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 50, 291-322.
20. Fromtling R.A. Overview of medically important antifungal azole derivatives. Clin. Microbiol. Rev. 1988, 1:187-217.
21. McLachlan A.J., Tett S.E. Pharmacokinetics of fluconazole in people with HIV infection: a population analysis. Br. J. Clin. Pharmacol. 1996, 41:291-298.
22. Rex J.H., et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. N. Engl. J. Med. 1994, 331:1325-1330.
23. Slavin M.A., et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation--a prospective, randomized, double-blind study. J. Infect. Dis. 1995, 171:1545-1552.
24. Dastghaib L., et al. Therapeutic options for the treatment of tinea capitis: griseofulvin versus fluconazole. J. Dermatolog. Treat. 2005, 16:43-46.
25. Denning D.W., et al. Treatment of invasive aspergillosis with itraconazole. Am. J. Med. 1989, 86:791-800.
26. Barone J.A., et al. Food interaction and steady-state pharmacokinetics of itraconazole oral solution in healthy volunteers. Pharmacotherapy 1998, 18:295-301.
27. Glasmacher A., et al. Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: evidence from a meta-analysis of 3,597 patients. J. Clin. Oncol. 2003, 21:4615-4626.
28. Zonios D.I., Bennett J.E. Update on azole antifungals. Semin. Respir. Crit. Care. Med. 2008, 29:198-210.
29. Eisen D.P., Robson J. Complete resolution of pulmonary Rhizopus oryzae infection with itraconazole treatment: more evidence of the utility of azoles for zygomycosis. Mycoses 2004, 47:159-162.
30. Lestner J.M., et al. Toxicodynamics of itraconazole: implications for therapeutic drug monitoring. Clin. Infect. Dis. 2009, 49:928-930.
31. Walsh T.J., et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin. Infect. Dis. 2008, 46:327-360.
32. Walsh T.J., et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N. Engl. J. Med. 2002, 346:225-234.
33. Torres H.A., et al. Posaconazole: a broad-spectrum triazole antifungal. Lancet Infect. Dis. 2005, 5:775-785.
34. Courtney R., et al. Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults. Br. J. Clin. Pharmacol. 2004, 57:218-222.
35. Courtney R., et al. Pharmacokinetics of posaconazole coadministered with antacid in fasting or nonfasting healthy men. Antimicrob. Agents Chemother. 2004, 48:804-808.
36. Cornely O.A., et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N. Engl. J. Med. 2007, 356:348-359.
37. Ullmann A.J., et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N. Engl. J. Med. 2007, 356:335-347.
38. Walsh T.J., et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin. Infect. Dis. 2007, 44:2-12.
39. Greenberg R.N., et al. Posaconazole as salvage therapy for zygomycosis. Antimicrob. Agents Chemother. 2006, 50:126-133.
40. Petranyi G., et al. Allylamine derivatives: new class of synthetic antifungal agents inhibiting fungal squalene epoxidase. Science 1984, 224:1239-1241.
41. Sigurgeirsson B., et al. Long-term effectiveness of treatment with terbinafine vs itraconazole in onychomycosis: a 5-year blinded prospective follow-up study. Arch. Dermatol. 2002, 138:353-357.
42. Gosbell I.B., et al. Cure of orthopaedic infection with Scedosporium prolificans, using voriconazole plus terbinafine, without the need for radical surgery. Mycoses 2003, 46:233-236.
43. Denning D.W. Echinocandin antifungal drugs. Lancet 2003, 362:1142-1151.
44. Petraitiene R., et al. Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia. Antimicrob. Agents Chemother. 2002, 46:12-23.
45. Gudlaugsson O., et al. Attributable mortality of nosocomial candidemia, revisited. Clin. Infect. Dis. 2003, 37:1172-1177.
46. Hassan I., et al. Excess mortality, length of stay and cost attributable to candidaemia. J. Infect. 2009, 59:360-365.
47. Reboli A.C., et al. Anidulafungin versus fluconazole for invasive candidiasis. N. Engl. J. Med. 2007, 356:2472-2482.
48. Kullberg B.J., et al. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet 2005, 366:1435-1442.
49. Mora-Duarte J., et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N. Engl. J. Med. 2002, 347:2020-2029.
50. Garcia-Effron G., et al. A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility. Antimicrob. Agents Chemother. 2008, 52:2305-2312.
51. Pappas P.G., et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin. Infect. Dis. 2007, 45:883-893.
52. Park S., et al. Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates. Antimicrob. Agents Chemother. 2005, 49:3264-3273.
53. Balashov S.V., et al. Assessing resistance to the echinocandin antifungal drug caspofungin in Candida albicans by profiling mutations in FKS1. Antimicrob. Agents Chemother. 2006, 50:2058-2063.
54. Garey K.W., et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin. Infect. Dis. 2006, 43:25-31.
55. Baquir B., et al. Immunological reactivity of blood from healthy humans to the rAls3p-N vaccine protein. J. Infect. Dis. 2010, 201:473-477.
56. Kauffman C.A., et al. Prospective multicenter surveillance study of funguria in hospitalized patients. The National Institute for Allergy and Infectious Diseases (NIAID) Mycoses Study Group. Clin. Infect. Dis. 2000, 30:14-18.
57. Kobayashi C.C., et al. Candiduria in hospital patients: a study prospective. Mycopathologia 2004, 158:49-52.
58. Hope W.W. Assessing candiduria in a critically ill patient. Br. Med. J. 2009, 338:b2289.
59. Tuon F.F., et al. Bladder irrigation with amphotericin B and fungal urinary tract infection-systematic review with meta-analysis. Int. J. Infect. Dis. 2009, 13:701-706.
60. Sobel J.D., et al. Candiduria: a randomized, double-blind study of treatment with fluconazole and placebo. The National Institute of Allergy and Infectious Diseases (NIAID) Mycoses Study Group. Clin. Infect. Dis. 2000, 30:19-24.
61. Lundstrom T., Sobel J. Nosocomial candiduria: a review. Clin. Infect. Dis. 2001, 32:1602-1607.
62. Hamza O.J., et al. Single-dose fluconazole versus standard 2-week therapy for oropharyngeal candidiasis in HIV-infected patients: a randomized, double-blind, double-dummy trial. Clin. Infect. Dis. 2008, 47:1270-1276.
63. Villanueva A., et al. A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis. Clin. Infect. Dis. 2001, 33:1529-1535.
64. de Wet N., et al. A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients. Clin. Infect. Dis. 2004, 39:842-849.
65. Krause D.S., et al. A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis. Clin. Infect. Dis. 2004, 39:770-775.
66. Sawyer S.M., et al. Vulvovaginal candidiasis in young women with cystic fibrosis. Br. Med. J. 1994, 308:1609.
67. Sobel J.D., et al. Treatment of vaginitis caused by Candida glabrata: use of topical boric acid and flucytosine. Am. J. Obstet. Gynecol. 2003, 189:1297-1300.
68. White D.J., et al. Combined topical flucytosine and amphotericin B for refractory vaginal Candida glabrata infections. Sex Transm. Infect. 2001, 77:212-213.
69. Moudgal V.V., Sobel J.D. Antifungal drugs in pregnancy: a review. Expert Opin. Drug Saf. 2003, 2:475-483.
70. Verweij P.E., et al. Azole resistance in Aspergillus fumigatus: a side-effect of environmental fungicide use?. Lancet Infect. Dis. 2009, 9:789-795.
71. Howard S.J., et al. Frequency and evolution of Azole resistance in Aspergillus fumigatus associated with treatment failure. Emerg. Infect. Dis. 2009, 15:1068-1076.
72. Denning D.W., Stevens D.A. Antifungal and surgical treatment of invasive aspergillosis: review of 2,121 published cases. Rev. Infect. Dis. 1990, 12:1147-1201.
73. Bates D.W., et al. Mortality and costs of acute renal failure associated with amphotericin B therapy. Clin. Infect. Dis. 2001, 32:686-693.
74. Wingard J.R., et al. Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. Clin. Infect. Dis. 1999, 29:1402-1407.
75. Ellis M., et al. An EORTC international multicenter randomized trial (EORTC number 19923) comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis. Clin. Infect. Dis. 1998, 27:1406-1412.
76. Denning D.W., et al. NIAID Mycoses Study Group multicenter trial of oral itraconazole therapy for invasive aspergillosis. Am. J. Med. 1994, 97:135-144.
77. Herbrecht R., et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N. Engl. J. Med. 2002, 347:408-415.
78. Nivoix Y., et al. Factors associated with overall and attributable mortality in invasive aspergillosis. Clin. Infect. Dis. 2008, 47:1176-1184.
79. Upton A., et al. Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality. Clin. Infect. Dis. 2007, 44:531-540.
80. Wheeler R.T., Fink G.R. A drug-sensitive genetic network masks fungi from the immune system. PLoS Pathog 2006, 2:e35.
81. Hohl T.M., et al. Caspofungin modulates inflammatory responses to Aspergillus fumigatus through stage-specific effects on fungal beta-glucan exposure. J. Infect. Dis. 2008, 198:176-185.
82. Lamaris G.A., et al. Caspofungin-mediated beta-glucan unmasking and enhancement of human polymorphonuclear neutrophil activity against Aspergillus and non-Aspergillus hyphae. J. Infect. Dis. 2008, 198:186-192.
83. Ouchi H., et al. Successful treatment of refractory chronic necrotizing pulmonary aspergillosis with micafungin. J. Infect. Chemother. 2007, 13:258-262.
84. Denning D.W., et al. Chronic cavitary and fibrosing pulmonary and pleural aspergillosis: case series, proposed nomenclature change, and review. Clin. Infect. Dis. 2003, 37(Suppl 3):S265-S280.
85. Camuset J., et al. Treatment of chronic pulmonary aspergillosis by voriconazole in nonimmunocompromised patients. Chest 2007, 131:1435-1441.
86. Crosdale D.J., et al. Mannose-binding lectin gene polymorphisms as a susceptibility factor for chronic necrotizing pulmonary aspergillosis. J. Infect. Dis. 2001, 184:653-656.
87. Sambatakou H., et al. Cytokine profiling of pulmonary aspergillosis. Int. J. Immunogenet. 2006, 33:297-302.
88. Vaid M., et al. Distinct alleles of mannose-binding lectin (MBL) and surfactant proteins A (SP-A) in patients with chronic cavitary pulmonary aspergillosis and allergic bronchopulmonary aspergillosis. Clin. Chem. Lab. Med. 2007, 45:183-186.
89. Jain L.R., Denning D.W. The efficacy and tolerability of voriconazole in the treatment of chronic cavitary pulmonary aspergillosis. J. Infect. 2006, 52:e133-137.
90. Snelders E., et al. Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism. PLoS Med. 2008, 5:e219.
91. Stevens D.A., et al. A randomized trial of itraconazole in allergic bronchopulmonary aspergillosis. N. Engl. J. Med. 2000, 342:756-762.
92. Wark P.A., et al. Anti-inflammatory effect of itraconazole in stable allergic bronchopulmonary aspergillosis: a randomized controlled trial. J. Allergy Clin. Immunol. 2003, 111:952-957.
93. Denning D.W., et al. Randomized controlled trial of oral antifungal treatment for severe asthma with fungal sensitization: The Fungal Asthma Sensitization Trial (FAST) study. Am. J. Respir. Crit. Care Med. 2009, 179:11-18.
94. Longley N., et al. Dose response effect of high-dose fluconazole for HIV-associated cryptococcal meningitis in southwestern Uganda. Clin. Infect. Dis. 2008, 47:1556-1561.
95. Nussbaum J.C., et al. Combination flucytosine and high-dose fluconazole compared with fluconazole monotherapy for the treatment of cryptococcal meningitis: a randomized trial in Malawi. Clin. Infect. Dis. 2010, 50:338-344.
96. Roden M.M., et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin. Infect. Dis. 2005, 41:634-653.
97. Kontoyiannis D.P., et al. Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J. Infect. Dis. 2005, 191:1350-1360.
98. Reed C., et al. Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis. Clin. Infect. Dis. 2008, 47:364-371.
99. Spellberg B., et al. Safety and outcomes of open-label deferasirox iron chelation therapy for mucormycosis. Antimicrob. Agents Chemother. 2009, 53:3122-3125.
100. Ben-Ami R., et al. Phaeohyphomycosis in a tertiary care cancer center. Clin. Infect. Dis. 2009, 48:1033-1041.